IDiyas

For the Inventor, By the Inventor

Westfield, NJ, United States of America

Kake Zhao

USPTO Granted Patents = 8 

 


Average Co-Inventor Count = 13.7

ph-index = 4

Forward Citations = 23(Granted Patents)


Company Filing History:

goldMedal8 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents

Years Active: 2015-2025

where 'Filed Patents' based on already Granted Patents

8 patents (USPTO):
1. 12466831 - Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use (2025-11-11),
2. 11884683 - Tricyclic heterocycle compounds useful as HIV integrase inhibitors (2024-01-30),
3. 10766919 - Cyclic di-nucleotide compounds as sting agonists (2020-09-08),
4. 10759825 - Cyclic di-nucleotide compounds as STING agonists (2020-09-01),
5. 10442819 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2019-10-15),
6. 9221834 - Cyclic amine substituted oxazolidinone CETP inhibitor (2015-12-29),
7. 9126976 - Substituted benzopiperazines as CETP inhibitors (2015-09-08),
8. 8957062 - Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment (2015-02-17),

Title: Kake Zhao: Innovator in HIV Research

Introduction

Kake Zhao is a prominent inventor based in Westfield, NJ, with a significant contribution to medical research through his seven patents. His work primarily focuses on innovative compounds aimed at combating HIV infection, showcasing his dedication to addressing critical health issues.

Latest Patents

Among Kake Zhao's notable inventions, two stand out. The first is a patent for Tricyclic Heterocycle Compounds, specifically designed as HIV integrase inhibitors. This invention pertains to a specific formula of compounds that, along with their pharmaceutically acceptable salts or prodrugs, are utilized in treating or preventing HIV infection. The second notable patent involves Cyclic di-nucleotide compounds classified as STING agonists. This innovative class of polycyclic compounds acts as inducers of type I interferon production, highlighting their potential as active agents in therapeutic applications.

Career Highlights

Kake Zhao is associated with Merck Sharp & Dohme Corporation, a leading company in the pharmaceutical industry. His innovations and continuous research have played a crucial role in advancing treatments for viral infections, particularly HIV. Zhao's work exemplifies the importance of research and development in pharmaceuticals, reflecting a commitment to improving global health.

Collaborations

Throughout his career, Kake Zhao has collaborated with talented individuals such as Matthew Lloyd Childers and Ryan D Otte. These partnerships have been instrumental in the development of innovative solutions and compounds, enhancing the overall impact of their collective research endeavors.

Conclusion

Kake Zhao's contributions to HIV research through his patent portfolio underline the significance of innovation in medicine. His work not only represents a leap forward in therapeutic possibilities but also inspires future inventors and researchers in the pursuit of groundbreaking solutions for global health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…